Shorter radiation with immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation followed by a combination of chemotherapy, immunotherapy, and a targeted drug (bevacizumab) for locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink the tumor enough for surgery while avoiding more extensive radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal adenocarcinoma (a type of cancer) that has not spread to other organs.
- Your tumor is located within 10 cm of the anal opening and is stage II or III (locally advanced).
- Your tumor shows normal levels of certain repair proteins (called pMMR) or is microsatellite stable (MSS).
- You have not had any prior treatment for this cancer, such as radiation, chemotherapy, or immunotherapy.
- You are between 18 and 75 years old and have a good daily activity level (ECOG 0 or 1).
- You are willing to provide tumor tissue and blood samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a shorter course of radiation combined with chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
Hear when a new Short-course Radiotherapy Plus Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.